12:00 AM
 | 
Apr 24, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tenofovir disoproxil fumarate: Phase II data; Phase III

Preliminary 48-week data from a Phase II study of 189 treatment-experienced HIV patients showed mean reductions in viral load of 0.68, 0.6 and 0.43 log copies/ml in patients receiving 300,...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >